

AMENDMENTS TO THE CLAIMS

1. (currently amended) A pharmaceutical composition of matter in the form of a solution concentrate ~~compromizing~~ comprising a cyclosporin dissolved in ~~DMSO~~ dimethyl sulfoxide (DMSO) wherein the concentration of cyclosporin is at least 0.1% by weight of the total composition.

2. (currently amended) A composition as in ~~claims~~ claim 1 wherein the cyclosporin is cyclosporin A.

3. (currently amended) A method for administering cyclosporin into cerebrospinal fluid spaces, ~~including intraventricular and intrathecal, in a patient, the improvement~~ which compromises:

providing cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said cyclosporin and DMSO solution by injection into the cerebrospinal fluid spaces to said patient.

4. (original) A method for administering cyclosporin by injection including intra-ocular, intravestibular, into or adjacent to the brain, or spinal cord into a patient, the improvement which compromises: providing cyclosporin dissolved in DMSO in a

pharmaceutically acceptable carrier, and administering said cyclosporin and DMSO solution by injection intra-ocular, intravestibular, into or adjacent to the brain, or spinal cord to said patient.

5. (original) A method for administering cyclosporin by injection including intravenous, intra-arterial or intraparenchymal, into a patient, the improvement which comprises: providing cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said cyclosporin and DMSO solution by injection into intravenous, intra-arterial or intraparenchymal spaces to said patient.

6. (original) A method for administering cyclosporin orally, rectally, nasally or dermally to a patient, the improvement which comprises: providing the cyclosporin dissolved in DMSO in a pharmaceutically acceptable carrier, and administering said cyclosporin and DMSO solution orally, rectally, nasally or dermally to said patient.

7. (previously amended) The method of claim 3 wherein the cyclosporin is cyclosporin A, or functional derivatives, metabolites, variants or salts thereof.

8. (currently amended) An article of manufacture comprising packaging material and pharmaceutical agent is therapeutically effective for reducing or preventing neuronal damage and for causing immunosuppression when administered in a therapeutically effective quantity, and wherein the packaging material comprises a label which indicates that the pharmaceutical agent can be used for reducing or preventing neuronal damage and for causing immunosuppression, and wherein said pharmaceutical agent comprises DMSO and a cyclosporin ~~such as cyclosporin A or a compound of the class of cyclosporins,~~ or functional derivatives, metabolites, variants or salts ~~of them~~ thereof, or a combination of the before said, either alone or in admixture with diluents, or additives.

9. (new) The article of manufacture according to claim 8, wherein the cyclosporin is selected from the group consisting of cyclosporin A and a compound of the class of cyclosporins.

10. (new) The method according to claim 3 wherein the administering cyclosporin into cerebrospinal fluid spaces is intraventricular and intrathecal.